The UK Clinical Trials Regulation (UK CTR) was signed into law on 11 April 2025, with a 12-month rollout now underway. It has been described by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as the “biggest regulatory shake-up of clinical trials in 20 years.”
The regulation sets out ambitious goals: to strengthen patient safety, speed up approvals, support innovation, and enable more people to take part in clinical trials.
One of its most notable features is the introduction of a combined review, which allows applicants to seek both ethics and regulatory approval through a single submission. This aims to reduce duplication and avoid unnecessary delays, without compromising trial oversight.
The new regulation aligns closely with the European Union’s Clinical Trial Regulation (EU CTR), which has been mandatory for all new clinical trial applications since 31 January 2023, with existing trials required to transition by January 2025.
Applications to the UK CTR will be submitted through the Integrated Research Application System (IRAS), which bears similarities to the EU’s Clinical Trial Information System (CTIS). These parallels should ease the transition for sponsors already familiar with EU requirements.
What the UK CTR means for research
Accelerating the process from application to first participant is a key priority. The MHRA has stated that the aim is to reduce the timeline by 100 days – from 250 days to 150 days. Whether this reduced timeline will accommodate requests for further information from ethics committees is to be seen. Such requests could potentially delay trial initiation, as trials cannot begin until all outstanding ethical issues have been resolved.
That is something we will be monitoring. Nevertheless, the goal of shortening the timeline is a positive step, and it is hoped that this will enable trials to get underway more quickly.
These reduced timelines complement MHRA’s broader efforts to streamline late-stage clinical trials through a Notification Scheme, allowing lower-risk Phase 3 and Phase 4 applications to be processed in as little as 14 days.
Bringing back clinical trials
All these steps are intended to attract more clinical trials back to the UK, which has experienced a notable decline in activity since Brexit. This is likely due to concerns over potential regulatory divergence from the EU. The UK CTR is expected to reassure sponsors that the regulatory burden will not be excessive, and that documentation requirements will largely mirror those in Europe.
Additionally, the efforts to reduce duplication through combined reviews and a single portal for submissions should help streamline the process and ease administrative burden for sponsors.
However, it is worth noting that if a clinical trial is classified as high risk and requires expert review, the process could become complex. Again, this is something we will be watching closely.
Attracting innovators across the board
Alongside the UK CTR, the MHRA and the National Health Service (NHS) are introducing initiatives to position the UK as an attractive destination for health innovation.
One such programme is DigiTrials, which aims to support and accelerate the development of new treatments by offering tools and services that streamline trial processes and enhance patient engagement.
The NHS is also working to bring innovative treatments to patients through partnerships such as an agreement with BioNTech to deliver precision cancer immunotherapies to up to 10,000 UK patients by 2030. This initiative will be supported by the Cancer Vaccine Launch Pad (CVLP), designed to help identify potentially eligible cancer patients. In May, BioNTech announced plans to expand its UK investment by up to £1 billion over the next decade, including the establishing of two new R&D centres, supported by a UK government grant.
When taken together, the UK CTR and these complementary programmes are expected to play a key role in boosting clinical trial and development innovation within the UK.
To fully leverage these initiatives, sponsors will need a solid understand of the UK’s evolving clinical trial requirements and how to benefit from the available programmes. A trusted, experienced regulatory partner will be essential in navigating this landscape.
The UK CTR has ambitious goals: to strengthen patient safety, speed up approvals, support innovation and enable more people to take part in clinical trials.